DB
IMCR icon

Dmitry Balyasny’s Immunocore IMCR Stock Holding History

Dmitry Balyasny’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-113,844
Closed -$3.43M – 3235
2026
Q1 		$3.43M Buy
+113,844
New +$3.68M ﹤0.01% 1536
2022
Q2 		– Sell
-52,174
Closed -$1.56M – 2943
2022
Q1 		$1.56M Buy
+52,174
New +$1.32M ﹤0.01% 1467

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Dmitry Balyasny's IMCR Position: Q2 2026 in Review

Dmitry Balyasny sold out of Immunocore (IMCR) in Q2 2026, closing a stake of 113,844 shares — an estimated $3.43M sold.

Dmitry Balyasny first reported a position in IMCR in Q1 2022 and held it in 2 quarters. The position peaked at $3.43M in Q1 2026. 136 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

  • Dmitry Balyasny reported no remaining Immunocore position as of Q2 2026 after selling out during the quarter.
  • Dmitry Balyasny sold 113,844 Immunocore shares in Q2 2026, an estimated $3.43M.
  • Dmitry Balyasny first reported a position in Immunocore in Q1 2022 and held it in 2 quarters.
  • Dmitry Balyasny's Immunocore position peaked at $3.43M in Q1 2026.
  • 136 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.